25 completed, 12 terminated, 7 recruiting, 3 active not recruiting. 26 Phase 1, 16 Phase 2, 4 Phase 3, 2 Phase 4, 1 Not applicable.
Follow Metastatic Castration Resistant Prostate Cancer: new trials by email Literature Review of Metastatic Castration Resistant Prostate Cancer trials Research Report on Metastatic Castration Resistant Prostate Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer SX-682, DTX - Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 120 | 2026-10-27 | 2026-10-22 |
| JUR-003 in Adult Patients With Metastatic Prostate Cancer JUR-003 - Metastatic Castration Resistant Prostate Cancer, Oligometastatic Prostate Cancer (OMPC) | Phase 1 | Recruiting | Juri Biosciences, Inc. | 210 | 2026-09-01 | 2026-10-15 |
| A Study to Learn About the Investigational Drug Rinzimetostat (ORIC-944) in Patients With mCRPC Who Were Previously Treated With Abiraterone Acetate (Himalayas-1) Rinzimetostat, Darolutamide, Enzalutamide - Metastatic Castration Resistant Prostate Cancer | Phase 3 | Recruiting | ORIC Pharmaceuticals | 600 | 2026-08-03 | 2026-10-05 |
| A Study in Patients With Metastatic Castration-Resistant Prostate Cancer FX-111 - Metastatic Castration Resistant Prostate Cancer, mCRPC | Phase 1 | Recruiting | Flare Therapeutics Inc. | 60 | 2026-07-01 | 2026-09-24 |
| 177Lu-PSMA-617 in Metastatic Castration Resistant Prostate Cancer (mCRPC) With Bone Marrow Involvement and Cytopenia 177Lu-PSMA-617 - Metastatic Castration Resistant Prostate Cancer, Cytopenia | Phase 2 | Withdrawn | M.D. Anderson Cancer Center | 2025-08-03 | 2026-05-08 | |
| Observational Study on Lutetium (177Lu) Vipivotide Tetraxetan to Treat Metastatic Castration Resistant Prostate Cancer Metastatic Castration Resistant Prostate Cancer | Recruiting | Novartis Pharmaceuticals | 300 | 2025-07-30 | 2026-05-15 | |
| Phase 1 Clinical Study of GT-220F in Subjects With Metastatic Castration Resistant Prostate Cancer (mCRPC) GT-220F capsule - Metastatic Castration Resistant Prostate Cancer | Phase 1 | Not yet recruiting | Geode Therapeutics Inc. | 42 | 2025-07-01 | 2025-03-10 |
| A Trial of HRS-5041-103 to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HRS-5041 in Subjects With Metastatic Castration-resistant Prostate Cancer HRS-5041 Single dose of HRS-5041 orally administered - Metastatic Castration Resistant Prostate Cancer | Phase 1 | Active not recruiting | Atridia Pty Ltd. | 25 | 2025-06-15 | 2026-10-14 |
| Real-world Experience With Lutetium Vipivotide Tetraxetan in Metastatic Castration Resistant Prostate Cancer lutetium (177Lu) vipivotide tetraxetan - Metastatic Castration Resistant Prostate Cancer | Recruiting | Novartis Pharmaceuticals | 500 | 2024-09-04 | 2026-07-13 | |
| A Study of AC176 for the Treatment of Metastatic Castration Resistant Prostate Cancer AC176 - Metastatic Castration Resistant Prostate Cancer | Phase 1 | Terminated | Accutar Biotechnology Inc | 8 | 2023-02-22 | 2024-01-25 |
| Radiometabolic Therapy (RMT) With 177Lu PSMA 617 in Advanced Castration Resistant Prostate Cancer (CRPC) 177Lu-PSMA - Metastatic Castration Resistant Prostate Cancer, 68Ga-PSMA PET/CT Positive | Phase 2 | Completed | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | 143 | 2022-10-25 | 2025-01-08 |
| A Study of AC176 for the Treatment of Metastatic Castration Resistant Prostate Cancer AC176 - Metastatic Castration Resistant Prostate Cancer | Phase 1 | Terminated | Accutar Biotechnology Inc | 28 | 2022-03-16 | 2025-02-13 |
| Trial of LAVA-1207 in Patients With Therapy Refractory Metastatic Castration Resistant Prostate Cancer (mCRPC) Resistant Prostate Cancer LAVA-1207, LAVA-1207 plus Pembrolizumab - Metastatic Castration Resistant Prostate Cancer | Phase 1 | Terminated | Lava Therapeutics | 96 | 2022-01-17 | 2025-08-01 |
| Targeted Alpha Therapy With 225Actinium-Prostate Specific Membrane Antigen (PSMA)-I&T of Castration-resISTant Prostate Cancer (TATCIST). FPI-2265 - Metastatic Castration Resistant Prostate Cancer | Phase 2 | Active not recruiting | Fusion Pharmaceuticals Inc. | 115 | 2021-12-16 | 2026-04-03 |
| IMU-935 in Patients With Progressive, Metastatic Castration Resistant Prostate Cancer IMU-935 - Metastatic Castration Resistant Prostate Cancer | Phase 1 | Terminated | Immunic AG | 18 | 2021-12-09 | 2024-01-17 |
| A Trial of SHR3162 Combined With Apatinib Mesylate Tablets or SHR3162 Monotherapy in Patients With Metastatic Castration Resistant Prostate Cancer Fluzoparib, Enzalutamide OR abiraterone acetate With Prednisone Acetate Tablets, Fluzoparib Combined With Apatinib - Metastatic Castration Resistant Prostate Cancer | Phase 2 | Completed | Jiangsu HengRui Medicine Co., Ltd. | 93 | 2021-07-19 | 2025-01-24 |
| A Phase 1 Study of Autologous Dendritic Cell Immunotherapy in Patients With mCRPC Cellgram-DC-PC - Metastatic Castration Resistant Prostate Cancer | Phase 1 | Terminated | Pharmicell Co., Ltd. | 3 | 2021-07-05 | 2026-09-21 |
| A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer PRL-02 injection, prednisone, dexamethasone - Prostate Cancer, Metastatic Castration Resistant Prostate Cancer | Phase 1 | Recruiting | Astellas Pharma Global Development, Inc. | 174 | 2021-06-14 | 2026-02-04 |
| Assess the Safety, Tolerability, PK and Anti-tumor Efficacy of DZD2269 in Patients With MCRPC DZD2269 - Metastatic Castration Resistant Prostate Cancer | Phase 1 | Terminated | Dizal Pharmaceuticals | 16 | 2021-04-12 | 2022-07-11 |
| Abiraterone Acetate in Combination With Tildrakizumab Abiraterone Acetate, Tildrakizumab - Metastatic Castration Resistant Prostate Cancer | Phase 1 / Phase 2 | Terminated | Institute of Cancer Research, United Kingdom | 13 | 2020-12-01 | 2024-04-25 |
Showing 20 of 50. Sign in to see all of them.
Prostatic Neoplasms (17) · Neoplasm Metastasis (6) · Carcinoma, Renal Cell (4) · Bulbo-Spinal Atrophy, X-Linked (3) · Carcinoma, Non-Small-Cell Lung (3) · Squamous Cell Carcinoma of Head and Neck (3) · Breast Neoplasms (2) · Carcinoma, Hepatocellular (2) · Colorectal Neoplasms (2) · Kidney Neoplasms (2) · Pancreatic Neoplasms (2) · Sarcoma (2) · Triple Negative Breast Neoplasms (2) · Adenoma, Islet Cell (1) · Anemia (1)
Neoplasms (21) · Male Urogenital Diseases (20) · Neoplasms by Site (20) · Urogenital Diseases (20) · Urogenital Neoplasms (20) · Genital Diseases (18) · Genital Diseases, Male (17) · Genital Neoplasms, Male (17) · Prostatic Diseases (17) · Pathologic Processes (7) · Pathological Conditions, Signs and Symptoms (7) · Neoplastic Processes (6) · Adenocarcinoma (5) · Neoplasms by Histologic Type (5) · Neoplasms, Glandular and Epithelial (5)
enzalutamide (16) · Abiraterone Acetate (6) · Docetaxel (4) · pembrolizumab (4) · Prednisone (3) · rucaparib (3) · Nivolumab (2) · Pluvicto (2) · ciforadenant (2) · Androgen Antagonists (1) · Biopsy (1) · Blood Specimen Collection (1) · CPI-006 (1) · Dexamethasone (1) · IT-101 (1)
Hinova Pharmaceuticals Inc. (3) · pharmaand GmbH (3) · Accutar Biotechnology Inc (2) · Astellas Pharma Europe Ltd. (2) · Astellas Pharma Global Development, Inc. (2) · Corvus Pharmaceuticals, Inc. (2) · Institute of Cancer Research, United Kingdom (2) · National Cancer Institute (NCI) (2) · Novartis Pharmaceuticals (2) · Radboud University Medical Center (2) · Astellas Pharma Inc (1) · Astellas Pharma a/s (1) · Atridia Pty Ltd. (1) · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (1) · Dizal Pharmaceuticals (1)
United States (24) · United Kingdom (11) · Australia (7) · Spain (7) · China (6) · France (6) · Germany (6) · Italy (6) · Belgium (5) · Netherlands (5) · Canada (4) · Switzerland (4) · Denmark (3) · Ireland (3) · South Korea (3)
Johann De Bono, MD (2) · Nielka van Erp, PharmD, PhD (2) · Ajjai Alva, MD (1) · Alok Tewari, MD, PhD (1) · Bagi Jana, MD (1) · Charalampos Floudas, M.D. (1) · Feng Bi, professor (1) · Giovanni Paganelli (1) · J. B., MD (1)
PMID 32203306, PMID 36898948, PMID 30065100, PMID 31815592, PMID 32408351, PMID 32430583, PMID 32897402, PMID 33632874, PMID 34109624, PMID 34246328, PMID 34333554, PMID 35397664, PMID 35640474, PMID 36229853, PMID 36265504, PMID 36600561, PMID 36795891, PMID 37277275, PMID 37844613, PMID 38324085, PMID 40610228, PMID 41926961
2016 (2), 2015 (1)